Researchers
-
Begoña Pina Marín
Ophthalmology
-
Carlos Luis Moser Würth
Ophthalmology
-
Carlos Martínez Belló
Ophthalmology
-
Diana Paola Mora Ramirez
Ophthalmology
-
Joan Josep Escobar Barranco
Ophthalmology
-
Josep Badal Lafulla
Ophthalmology
Phd -
Luis Amselem Gómez
Ophthalmology
-
Magela Garat Chifflet
Ophthalmology
-
Manel Fernández Bonet
Ophthalmology
-
Monica Lecumberri López
Ophthalmology
-
Rafael Alcubierre Bailac
Ophthalmology
-
Sabrina Bojados
Ophthalmology
-
Stephanie Carrillo
Ophthalmology
Contact the group
Form
Projects
-
Ophthalmology
Researcher
- Year 2016
- Comprehensive Care Center Dos de Maig Hospital
Exploratory, randomised, double-masked and placebo-controlled study to evaluate the pharmacodynamics, safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with visual impairment due to central predominance diabetic macular edema,
-
DISTRICT ATTORNEY:
Boehringer Ingelheim España, SA
-
TYPE E:
RD2015
-
- Year 2016
- Comprehensive Care Center Dos de Maig Hospital
Multicenter, randomized, human intervention study of nutritional supplementation in patients with unilateral wet AMD,
-
DISTRICT ATTORNEY:
Thea Laboratories
-
TYPE E:
PINE TREE
-
- Year 2016
- Dos de Maig Hospital Integral Care Center
Intravitreal ranibizumab in diabetic macular edema: clinical practice results,
-
DISTRICT ATTORNEY:
Jose Juan Escobar
-
TYPE E:
PI
-
- Year 2016
- Dos de Maig Hospital Integral Care Center
Multicenter, randomized, human intervention study of nutritional supplementation in patients with unilateral wet AMD,
-
DISTRICT ATTORNEY:
Thea Laboratories
-
TYPE E:
PI
-
- Year 2016
- Comprehensive Care Center Dos de Maig Hospital
Exploratory, randomized, double-masked and placebo-controlled study to evaluate the pharmacodynamics, safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with visual impairment due to central predominance diabetic macular edema,
-
DISTRICT ATTORNEY:
Boehringer Ingelheim España, SA
-
TYPE E:
RD2015
-
- Year 2016
- Dos de Maig Hospital Integral Care Center
Exploratory, randomised, double-masked and placebo-controlled study to evaluate the pharmacodynamics, safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with visual impairment due to central predominance diabetic macular edema,
-
DISTRICT ATTORNEY:
Boehringer Ingelheim España, SA
-
TYPE E:
RD2015
-
- Year 2016
- Comprehensive Care Center Dos de Maig Hospital
Interventional study in phase IV, multicenter and of a single group to evaluate a guideline to treat and extend with intravitreal aflibercept for the treatment of macular edema secondary to occlusion of the central vein of the retina,
-
DISTRICT ATTORNEY:
Bayer AG
-
TYPE E:
RD2015
-
- Year 2016
- Dos de Maig Hospital Integral Care Center
Interventional study in phase IV, multicenter and of a single group to evaluate a guideline to treat and extend as intravitreal aflibercept for the treatment of secondary macular edema in the occlusion of the central vein of the retina,
-
DISTRICT ATTORNEY:
Bayer AG
-
TYPE E:
RD2015
-
- Year 2016
- Comprehensive Care Center Dos de Maig Hospital
Intravitreal ranibizumab in diabetic macular edema: clinical practice results,
-
DISTRICT ATTORNEY:
Jose Juan Escobar
-
TYPE E:
PINE TREE
-
Ophthalmology
Researcher
- Year 2015
- Comprehensive Care Center Dos de Maig Hospital
A two-year, randomized, double-masked, multicenter, two-group study to compare the efficacy and safety of RTH258 6 mg in combination with aflibercept in subjects with exudative age-related macular degeneration,
-
DISTRICT ATTORNEY:
Alcon Research, Ltd.
-
TYPE E:
RD2004
Lines of action
- Treatment of retinal diseases with intravitreal medication
- Anti VEGF in diabetic macular edema
- Anti VEGF in central serous chorioretinopathy
- Treatment of Diabetic Retinopathy
- UTI (Intravitreal Therapy Unit)
- New techniques in cataract surgery
- Surgical alternatives to full thickness corneal transplantation
- Microkeratum assisted keratoplasty Anterior and posterior lamellar techniques
